Clinical Trial Update: Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance [NA]

View source ↗

Summary

Clinical trial evaluating recombinant human insulin-like growth factor I in patients with severe insulin resistance has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperglycemia
• Insulin Resistance

Drugs mentioned

• Recombinant human insulin-like growth factor I (mecasermin) (mecasermin)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Insulin Resistance, Hyperglycemia | NA | Status: COMPLETED